UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrolling By Invitation
18 years - 99 years
All
Phase
3
5 participants needed
1 Location
Brief description of study
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
Detailed description of study
The loss of enjoyment of food and weight loss has shown to decrease the quality of life for cancer patients. Additionally, poor eating and weight loss affects patients’ overall health, making them increasingly tired and more likely to experience side effects from their cancer treatments. Some patients have to take lower doses of cancer-fighting treatments or stop using them altogether.
Anamorelin HCl, works by mimicking a naturally occurring substance in the body that causes increased appetite and weight gain.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: BMI
-
Age: 18 years - 99 years
-
Gender: All
- Female or male ≥18 years of age
- Documented diagnosis of Stage III or IV Non-Small Cell Lung Cancer.
- Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening.
Updated on
04 Aug 2024.
Study ID: 832183
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
